NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2026)

NewAmsterdam Pharma has disclosed Profit After Tax across 4 years of filings, most recently posting -$48.4 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$48.4 million, down 22.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$212.7 million (down 13.54% YoY), and the FY2025 annual result was -$203.8 million, up 15.64% from the prior year.
• Profit After Tax came in at -$48.4 million for Q1 2026 at NewAmsterdam Pharma, up from -$74.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
• The 4-year median for Profit After Tax is -$47.1 million (2023), against an average of -$51.6 million.
• Across the five-year window, Profit After Tax soared 64.68% in 2024 and tumbled 332.54% in 2025, its largest moves.
• NewAmsterdam Pharma's Profit After Tax stood at -$49.5 million in 2023, then sank by 86.34% to -$92.2 million in 2024, then grew by 18.72% to -$74.9 million in 2025, then soared by 35.35% to -$48.4 million in 2026.
• The last three Profit After Tax figures came in at -$48.4 million (Q1 2026), -$74.9 million (Q4 2025), and -$72.0 million (Q3 2025), per Business Quant data.